IFF sales
This article was originally published in The Rose Sheet
Executive Summary
Third quarter North America fine fragrance and functional fragrance sales grew 17% and 9%, respectively, flavors and fragrances manufacturer reports Oct. 28. Consolidated sales grew 5% on a reported basis, or 2% at constant exchange rates, to $506.2 mil. Income results included $20 mil. in pre-tax restructuring and other charges related to the sale of certain European fruit business assets to Fruitarom and closure of Dijon, France manufacturing facility. Net income dropped 17% including the restructuring charges to $51 mil. Excluding the impact of the charges, net income increased 3%. IFF anticipates low to mid-single digit sales growth for the year in local currency, or high-single digit growth on a reported basis...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.